Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Chinese Journal of Cancer Biotherapy is Scopus-indexed (Q4, CiteScore 0.2). Published by Editorial office of Chinese Journal of Cancer Biotherapy.
Checked against the index lists dated .
ISSN 1007-385XVerify ISSN ↗
Publisher: Editorial office of Chinese Journal of Cancer Biotherapy
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 316 / 328 | 3rd | Q4 |
| Cancer Research | 228 / 233 | 2nd | Q4 |
| Molecular Medicine | 179 / 179 | 0th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present (also 2013–2016, 2008–2011), best quartile Q4, CiteScore 0.2.
Chinese Journal of Cancer Biotherapy is Q4 in Pharmacology (rank 316 of 328), Q4 in Cancer Research (rank 228 of 233) and Q4 in Molecular Medicine (rank 179 of 179), by CiteScore 2025.
Chinese Journal of Cancer Biotherapy is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.2, quartile Q4, 3rd percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.108, quartile Q4, with an H-index of 5.
Chinese Journal of Cancer Biotherapy is published by Editorial office of Chinese Journal of Cancer Biotherapy. Its ISSN is 1007-385X.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.